课题基金 / 基金详情

Analysis of oncogenic signal transduction and target genes by constitutive active mutations of c-Kit and Flt3

Analysis of oncogenic signal transduction and target genes by constitutive active mutations of c-Kit and Flt3
c-Kit和Flt3组成型活性突变分析致癌信号转导和靶基因
批准号:
14570977
负责人:
MIZUKI Misao
金额:
$2.24万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2003

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
1. Flt3 mutation specific target genesMicrochip analysis revealed that Flt3 internal tandem duplication (Flt3-ITD) mutation specifically induced STAT3/5 target genes such as pim-2, SOCS3 and CIS. These genes were also induced by constitutive active, c-Kit mutations. Pim-2 was.highly expressed in the leukemic cells form AML patients compared to normal bone marrow cells, which suggested that STAT3/5-pim2 was the common oncogenic signaling pathway in AML. Flt3-ITD specifically suppressed myeloid-specific transcription factors such as C/EBPalpha and PU.1, which suggested that Flt3-ITD is involved in the differentiation block in AML.2. Gytoplasmic tyrosine residues involved in the activation and siganl transduction of receptor tyrosine kinasesWe analyzed effects of phenylalanine conversion of 22 tyrosine residues in the cytoplasmic domain of c-Kit of Flt3 on receptor activation, down stream signal transduction and cell function. In the c-Kit kinase domain mutant, Phe-substitution of Tyr719 abolished the binding of p85 PI3-kinase subunit, the kinase activity of receptor itself and the proliferative activity. In the Flt3 kinase domain mutant, Phe-substitution of Tyr845, 892 and 922 suppressed the kinase activity, downstream signal transduction such as Erk1/2 and STAT3/5, factor-independent growth and survival. These results suggested that specific tyrosine residues criticallyregulated the oncogemc acivation of kinase domain muta its of receptor tyrosine kinases.
期刊论文(114)
专著(0)
科研奖励(0)
会议论文
Shuji Ueda: "Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296"Int.J.Hematol. 76. 427-435 (2002)
Shuji Ueda:“酪氨酸激酶抑制剂 STI571 和 AG1296 选择性地抑制近膜而非催化结构域突变对 c-kit 的组成性激活”Int.J.Hematol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Zhang, X. et al.: "Constitutively activated Rho GTPases regulate the growth and morphology of hairy cell leukemia (HCL) cells."Int.J.Hematology. 77. 263-273 (2003)
张,X. 等人:“组成型激活的 Rho GTP 酶调节毛细胞白血病 (HCL) 细胞的生长和形态。”Int.J.Hematology。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Matsumura, I. et al.: "Molecular mechanisms of E2F1-and c-Myc-enhanced apoptosis."Recent Research Developments in Molecular & Cellular Biology. 4. 311-324 (2003)
Matsumura, I. 等人:“E2F1 和 c-Myc 增强细胞凋亡的分子机制。”分子生物学的最新研究进展
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Matsumura, I. et al.: "Cell cycle regulation in hematopoietic stem cells."Res.Adv.in Blood. 2. 39-49 (2003)
Matsumura, I. 等人:“造血干细胞的细胞周期调节。”Res.Adv.in Blood。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
55
    国内基金
    海外基金
    配子生成素GGN不同位点突变损伤分子伴侣BIP及HSP90B1功能导致精子形成障碍的发病机理
    • 批准号:
      82371616
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2023
    • 负责人:
      姚晨成
    • 依托单位:
    Pik3r2基因突变在家族内侧颞叶癫痫中的作用及发病机制研究
    • 批准号:
      82371454
    • 项目类别:
      面上项目
    • 资助金额:
      47.00万元
    • 批准年份:
      2023
    • 负责人:
      郝勇
    • 依托单位:
    GREB1突变介导雌激素受体信号通路导致深部浸润型子宫内膜异位症的分子遗传机制研究
    • 批准号:
      82371652
    • 项目类别:
      面上项目
    • 资助金额:
      45.00万元
    • 批准年份:
      2023
    • 负责人:
      刘开江
    • 依托单位:
    22q11.2染色体微重复影响TOP3B表达并导致腭裂发生的机制研究
    • 批准号:
      82370906
    • 项目类别:
      面上项目
    • 资助金额:
      48.00万元
    • 批准年份:
      2023
    • 负责人:
      代杰文
    • 依托单位: